How We Reached This Point
Historically, FDA has recommended that ARVs be studied in broad patient population and has provided for flexibility in endpoint, however ...
Registrational studies largely conducted in na´ve or NRTI-experienced population
- Evolving treatment since trial initiation
- New drug may not be expected to be effective due to cross-resistance
- Challenges of trial design and data interpretation in experienced population